球三糖神经酰胺
法布里病
腺相关病毒
肾
α-半乳糖苷酶
遗传增强
溶酶体贮存病
内分泌学
病毒
酶
内科学
生物
分子生物学
生理盐水
化学
基因
医学
病毒学
载体(分子生物学)
生物化学
疾病
重组DNA
作者
Yuka Hayashi,Yoshihide Sehara,Ryota Watano,Kenji Ohba,Yuki Takayanagi,Kazuhiro Muramatsu,Yoshio Sakiyama,Hiroaki Mizukami
摘要
Abstract Background Fabry disease (FD) is an inherited lysosomal storage disease caused by deficiency of α‐galactosidase A (α‐Gal A) encoded by the GLA gene. The symptoms of FD occur as a result of the accumulation of globotriaosylceramide (Gb3), comprising a substrate of α‐Gal A, in the organs. Adeno‐associated virus (AAV)‐mediated gene therapy is a promising treatment for FD. Methods α‐Gal A knockout (GLAko) mice were injected intravenously with AAV2 (1 × 1011 viral genomes [vg]) or AAV9 (1 × 1011 or 2 × 1012 vg) vectors carrying human GLA (AAV‐hGLA), and plasma, brain, heart, liver and kidney were tested for α‐Gal A activity. The vector genome copy numbers (VGCNs) and Gb3 content in each organ were also examined. Results The plasma α‐Gal A enzymatic activity was three‐fold higher in the AAV9 2 × 1012 vg group than wild‐type (WT) controls, which was maintained for up to 8 weeks after injection. In the AAV9 2 × 1012 vg group, the level of α‐Gal A expression was high in the heart and liver, intermediate in the kidney, and low in the brain. VGCNs in the all organs of the AAV9 2 × 1012 vg group significantly increased compared to the phosphate‐buffered‐saline (PBS) group. Although Gb3 in the heart, liver and kidney of the AAV9 2 × 1012 vg was reduced compared to PBS group and AAV2 group, and the amount of Gb3 in the brain was not reduced. Conclusions Systemic injection of AAV9‐hGLA resulted in α‐Gal A expression and Gb3 reduction in the organs of GLAko mice. To expect a higher expression of α‐Gal A in the brain, the injection dosage, administration route and the timing of injection should be reconsidered.
科研通智能强力驱动
Strongly Powered by AbleSci AI